*Screening for Albuminuria at the first line for early identification of chronic kidney disease

*Screening for Albuminuria at the first line for early identification of chronic kidney disease - SALINE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54293

Enrollment

112

Registered

2021-10-12

Start date

2021-11-25

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diabetes Mellitus (diagnosis or prescription for the disease based on the NHG guidelines) Adipositas (diagnosis) Hypertension (diagnosis or prescription for the disease based on the NHG guidelines) Cardiovascular disease (diagnosis, specified in protocol section 4.2.2) Lipid disorder (diagnosis or prescription for the disease based on the NHG guidelines) Age 45-80 years

Exclusion criteria

Exclusion criteria: Pregnancy Inability to write or understand the informed consent form Known normal (

Design outcomes

Primary

Measure	Time frame
1. Elevated albuminuria, defined as a urinary albumin creatinine ratio (UACR) >= 3.0 mg/mmol. 2. Average screening costs per subject that was identified as having elevated albuminuria. All costs considered are mentioned in chapter 8.1.1.	—

Secondary

Measure	Time frame
1. Unrecognized chronic kidney disease, defined as elevated albuminuria, not reported by the subject or previously recorded in electronic medical records of the subjects* general practice or pharmacy. 2. Persistent elevated albuminuria, defined as elevated albuminuria persisting despite good adherence (score 4 (=doses seldom missed) or 5 (= doses never missed) reported in MARS) to treatment with RAS-inhibitors for at least 6 weeks prior to elevated albuminuria assessment 3. Change in frequency of cardiovascular risk factor monitoring, defined as the difference between the frequency of cardiovascular risk factor monitoring in participants 3 years before and 6 months after targeted albuminuria screening. 4. Changes in cardiometabolic drug prescriptions, defined as changes in any prescription for cardiovascular disease or CKD 6 months after targeted albuminuria screening compared to three years before.	—

Measure

Time frame

1. Unrecognized chronic kidney disease, defined as elevated albuminuria, not reported by the subject or previously recorded in electronic medical records of the subjects* general practice or pharmacy. 2. Persistent elevated albuminuria, defined as elevated albuminuria persisting despite good adherence (score 4 (=doses seldom missed) or 5 (= doses never missed) reported in MARS) to treatment with RAS-inhibitors for at least 6 weeks prior to elevated albuminuria assessment 3. Change in frequency of cardiovascular risk factor monitoring, defined as the difference between the frequency of cardiovascular risk factor monitoring in participants 3 years before and 6 months after targeted albuminuria screening. 4. Changes in cardiometabolic drug prescriptions, defined as changes in any prescription for cardiovascular disease or CKD 6 months after targeted albuminuria screening compared to three years before.

—

Countries

Netherlands

Outcome results